Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Update on the AML treatment landscape

Thorsten Braun • 29 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine Daunorubicin Venetoclax

Thorsten Braun, MD, PhD, Hôpitaux de Paris, Université Paris 13, Bobigny, France, outlines the current landscape and future directions in treating patients with acute myeloid leukemia (AML). Dr Braun discusses targeted therapies, liposomal daunorubicin/cytarabine and venetoclax-based therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thorsten Braun

1:21
Intensive therapy of older AML
Thorsten Braun • 29 Jun 2020
1:24
Leukemia treatment in times of COVID-19
Thorsten Braun • 29 Jun 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals